NEVRO CORP.
NVRO
NVRO was delisted on the 2nd of April, 2025.
176 hedge funds and large institutions have $1.52B invested in NEVRO CORP. in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 86 increasing their positions, 52 reducing their positions, and 30 closing their positions.
65% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 52
3% less call options, than puts
Call options by funds: $11.5M | Put options by funds: $11.8M
10% less funds holding
Funds holding: 195 → 176 (-19)
42% less capital invested
Capital invested by funds: $2.62B → $1.52B (-$1.1B)
47% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 30
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$44.4M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$29.8M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$19.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17M |
| 5 |
FAM
Fred Alger Management
New York
|
+$17M |
Top Sellers
NVRO Hedge Fund Activity: Q2 2022 in Review
176 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in NEVRO CORP. (NVRO) for Q2 2022, worth a combined $1.52B — down 42% from $2.62B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of NVRO and 16 opened new positions — a net loss of 14 holders — while 52 trimmed existing stakes and 86 added.
The largest buyer was Federated Hermes, adding an estimated $44.4M. The largest seller was T. Rowe Price Associates, cutting an estimated $114M.
- 176 institutional investors held NEVRO CORP. (NVRO) as of Q2 2022, down from 195 in Q1 2022.
- Funds reported $1.52B of NEVRO CORP. stock for Q2 2022, down 42% quarter-over-quarter.
- 16 funds opened new NEVRO CORP. positions in Q2 2022 and 30 closed out, a net change of -14 holders.
- The largest NEVRO CORP. buyer in Q2 2022 was Federated Hermes, an estimated $44.4M added.
- The largest NEVRO CORP. seller in Q2 2022 was T. Rowe Price Associates, an estimated $114M sold.
Based on aggregated 13F filings for Q2 2022.